Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer

BackgroundCurrently, the prognosis for metastatic colorectal cancer (mCRC) remains unfavorable. However, as advancements in local and systemic treatment modalities progress, therapeutic strategies for mCRC are becoming increasingly varied. For patients presenting with a limited number of metastases,...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Wei Qian, Huatang Zhang, Yanhua Mo, Chaoyang Wu, Juntong Liu, Yuyi Pen, Cantu Fang, Jincheng Meng
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-02-01
Edice:	Frontiers in Oncology
Témata:	fruquintinib immunotherapy metastatic colorectal cancer microwave ablation tislelizumab
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1728876/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!